Advances in atopic dermatitis and urticaria, 2016

This review highlights recent key advances in the pathology and therapies of inflammatory skin diseases, focusing on atopic dermatitis (AD) and chronic spontaneous urticaria (CSU). Regarding AD, transcriptomic analysis using human samples revealed different immune profiles between childhood AD and adult AD. Phase III clinical trials of dupilumab, an anti-IL4 receptor alpha antibody, on AD have successfully finished, and dupilumab will appear in clinical practice as the first biologics for AD in 2017.

http://ift.tt/2sMwSQR